Company news
Peptidream Inc. (TSE:4587) news
Every Peptidream Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Consolidated Financial Results for the Six Months Ended June 30, 2026 [IFRS]
August 12, 2026
Initiation of Phase 1 Clinical Trial by Novartis Marks Milestone for PeptiDream
August 11, 2026
PeptiDream Strengthens Leadership Team with Multiple Key Executive Appointments
July 2, 2026
PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
June 11, 2026
PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
June 11, 2026
PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner
April 20, 2026
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues
December 18, 2025
PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis
December 17, 2025
PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
October 15, 2025
PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment
December 12, 2024
PeptiDream Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer
December 12, 2024
NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma
June 4, 2024
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
April 30, 2024
PeptiDream Announces Initial Public Offering of RayzeBio and Update on GPC3 Program
September 20, 2023